Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roll Over Study for Continued Olaparib Treatment in Oncology Patients
2019-003777-26Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of olaparib in ovarian cancer, epithelial ovarian cancer (EOC), breast cancer and 2 more, sponsored by AstraZeneca. Primary endpoint: SAEs and AESIs. Started Apr 2020; status: active.
02
Drugs
olaparib
03
Conditions
ovarian cancerepithelial ovarian cancer (EOC)breast cancerpancreatic cancer (PC)cancer
Beyond the preview
Go deeper on 2019-003777-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003777-26.